RCTs included in the 2016 Chinese guideline for PCI
| Study ID | N | No. of centres | Enrolment period | Follow-up duration | CoR | LoE | Trial registration no. |
| Yang 200834 | 60 | N/R | August–October 2006 | 90 days | |||
| Zhang 201113 (REVERSE-STEMI) | 334 | 5 | November 2005–November 2007 | 1 year | IIb | B | NCT00713557 |
| Han 201335 | 197 | 4 | Not reported | 1 year | NCT01642667 | ||
| Zhu 2013 (ICT-AMI)36 | 453 | N/R | June 2006–March 2010 | 6 months | |||
| Geng 201437 | 535 | 1 | March 2012–February 2013 | 30 days | |||
| Han 2014 (I-LOVE-IT 2)38 | 2737 | 32 | October 2012–June 2013 | 12 months | I | B | NCT01681381 |
| Han 2014 (TRACK-D)39 | 2998 | 53 | December 2008–October 2011 | 30 days | IIa | A | NCT00786136 |
| Xu 2014 (PEPCAD China ISR)40 | 220 | 17 | March 2011–April 2012 | 12 months | I | A | NCT01622075 |
| Zhou 201541 | 621 | 1 | May 2009–May 2013 | 6 months | |||
| Chen 2015 (DKCRUSH-VI)42 | 320 | 8 | November 2011–June 2013 | 12 months | ChiCTR-TRC-07000015 | ||
| Gao 2015 (ABSORB China)43 | 480 | 24 | July 2013–March 2014 | 1 year | NCT01923740 | ||
| Li 201544 | 48 | 1 | April–November 2014 | 6 months | ChiCTR-RCS-14004303 | ||
| Han 2015 (BRIGHT)45 | 2194 | 82 | August 2012–June 2013 | 1 year | I | A | NCT01696110 |
| Zhang B 2015 (ISCAP)46 | 2674 | 50 | N/R | 6 months | NCT01293097 | ||
| Qian 201647 | 264 | 1 | February 2014–February 2015 | 90 days | NCT02405377 |
ABSORB China, A Clinical Evaluation of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) System in Chinese Population; BRIGHT, Bivalirudin in Acute Myocardial Infarction vs Heparin and GPI Plus Heparin Trial; CoR, class of recommendation; DKCRUSH-VI, Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions VI; I-LOVE-IT 2, Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization; ISCAP, Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention; LoE, Level of Evidence; N/R, not reported; PCI, percutaneous coronary intervention; PEPCAD China ISR, A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis; RCT, randomised controlled trial; TRACK-D, Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes.